Rituximab
not tagged
['persisti', 'lyma']
sarkozy et al - 7y fu of lyma (r mx v obs post asct 11l mcl)
- persisting v signif efs and pfs benefit
- 7y pfs 79% v 47%
- os benefit seen but no longer stat signif
- pod24 pts doing v badly (not many had btki)
- relapse after mxr do worse than relapse on obsv
#17icml 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.